Novel 3,4-dihydroquinolin-2(1H)-one derivatives as dual inhibitor targeting AKR1B1/ROS for treatment of diabetic complications: Design, synthesis and biological evaluation
Authors:
- 1 December 2020
- journal article
- research article
- Published by Elsevier in Bioorganic Chemistry
- Vol. 105, 104428
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- A series of pyrido[2,3-b]pyrazin-3(4H)-one derivatives as aldose reductase inhibitors with antioxidant activityEuropean Journal of Medicinal Chemistry, 2016
- Design and Synthesis of Potent and Multifunctional Aldose Reductase Inhibitors Based on QuinoxalinonesJournal of Medicinal Chemistry, 2015
- Targeting Aldose Reductase for the Treatment of Diabetes Complications and Inflammatory Diseases: New Insights and Future DirectionsJournal of Medicinal Chemistry, 2014
- Structure–activity relationships and molecular modelling of new 5-arylidene-4-thiazolidinone derivatives as aldose reductase inhibitors and potential anti-inflammatory agentsEuropean Journal of Medicinal Chemistry, 2014
- Endogenous fructose production and metabolism in the liver contributes to the development of metabolic syndromeNature Communications, 2013
- Aldose Reductase Enzyme and its Implication to Major Health Problems of the 21st CenturyCurrent Medicinal Chemistry, 2009
- Acetic Acid Aldose Reductase Inhibitors Bearing a Five-Membered Heterocyclic Core with Potent Topical Activity in a Visual Impairment Rat ModelJournal of Medicinal Chemistry, 2008
- Pyrido[1,2-a]pyrimidin-4-one Derivatives as a Novel Class of Selective Aldose Reductase Inhibitors Exhibiting Antioxidant ActivityJournal of Medicinal Chemistry, 2007
- Substituted Pyrrol-1-ylacetic Acids That Combine Aldose Reductase Enzyme Inhibitory Activity and Ability To Prevent the Nonenzymatic Irreversible Modification of Proteins from MonosaccharidesJournal of Medicinal Chemistry, 2002
- Biochemistry and molecular cell biology of diabetic complicationsNature, 2001